SpyGlass Pharma, Inc. — Form 8-K Summary
Business context and reporting period
The 8-K reports events dated October 1, 2026. SpyGlass Pharma acquired all outstanding shares of Advanced Vision Science, Inc. (AVS), its existing intraocular lens supplier, from Santen Holdings US, Inc. The transaction closed on October 1, 2026.
Financial and transaction details
- The purchase price was based on $13 million, subject to customary adjustments. The amount was estimated at closing and remains subject to a customary post-closing adjustment.
- The filing provides no clear figures for revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics, and does not quantify the acquisition’s financial impact.
Material changes and arrangements
- AVS will continue manufacturing and supplying Eternity-brand intraocular lenses to Santen Pharmaceutical Co., Ltd. under an amended supply and distribution agreement.
- Santen received an exclusive right to sell those products in Japan, subject to the agreement’s terms.
- The parties also entered into cross-license agreements covering certain intellectual property. The licenses are non-exclusive; AVS’s license to Santen is non-sublicensable.
Management commentary, risks, and unusual items
The filing describes customary representations, warranties, and covenants. Santen Pharmaceutical Co., Ltd. guaranteed the seller’s obligations under the purchase agreement, including indemnification obligations. The filing does not provide further details about the post-closing adjustment, indemnity limits, or expected operating effects. It references an October 1 press release as Exhibit 99.1, but the press release text is not included in the supplied filing text.
Key facts for investors to verify
- The final purchase price after the post-closing adjustment.
- AVS’s financial contribution and the acquisition’s effect on SpyGlass Pharma’s liquidity and results.
- The detailed terms, duration, and economics of the supply, Japan distribution, and intellectual-property agreements.
- Any additional transaction rationale or outlook stated in the referenced press release.